| Status: Medicine does not meet criteria for AWMSG assessment | |
Excluded from appraisal by AWMSG as meets exclusion criteria 6. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information. |
|
Medicine details |
|
| Medicine name | exenatide (Bydureon®) |
| Formulation | 2 mg powder and solvent for prolonged-release suspension for injection |
| Reference number | 2738 |
| Indication | Treatment of type 2 diabetes mellitus in combination with metformin, sulphonylurea, thiazolidinedione, metformin and sulphonylurea, metformin and thiazolidinedione, in adults who have not achieved adequate glycaemic control on maximally tolerated doses of these oral therapies |
| Company | AstraZeneca UK Ltd |
| BNF chapter | Endocrine system |
| Assessment type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 09/04/2015 |